
    
      This is an open label phase 2 trial assessing the efficacy and safety of anti-SARS-CoV-2
      convalescent plasma in hospitalized patients with acute severe respiratory symptoms from
      COVID-19. Symptomatic patients with clinical or radiological interstitial COVID-19 pneumonia
      and within 21 days of onset of symptoms will be enrolled in 2 cohorts - an ICU cohort and a
      hospitalized non-ICU cohort.
    
  